Addition of Veliparib to Cyclophosphamide Ineffective for Ovarian Cancer
the Cancer Therapy Advisor take:
In a phase 1 clinical trial, veliparib, a (ADP-ribose) polymerase (PARP) inhibitor, combined with oral cyclophosphamide showed promising clinical activity in patients with BRCA-mutant solid tumors.
Investigators conducted a randomized phase 2 trial to define the relative contribution of PARP inhibition that was previously observed.
In this study, investigators looked to evaluate the response rate of veliparib in combination with cyclophosphamide compared to cyclophosphamide alone in patients with pretreated BRCA-mutant ovarian cancer or patients with pretreated primary peritoneal, fallopian tube, or high-grade serous ovarian cancers (HGSOC).
There were 75 patients in the study that were randomly assigned to receive either veliparib with cyclophosphamide (n= 37) or cyclophosphamide alone (n=38). The results showed one complete response in each arm, and three partial responses (PR) in the combination arm and six in the cyclophosphamide arm.
A genetic sequence and expression analysis was performed on 221 genes involved in DNA repair and revealed that there was no significant genetic alteration associated with treatment benefit.
Overall, the authors concluded that the addition of veliparib to cyclophosphamide did not improve either response rate or the median progression free survival. However, for the first time, investigators found that single-agent low-dose cyclophosphamide provided some clinical activity in the treatment of HGSOC, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers.
Veliparib combined with oral cyclophosphamide showed promising clinical activity in BRCA-mutant solid tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma